Abigail "Abbey" L. Jenkins joined the Board of Directors in April 2024. Currently serving as President & Chief Executive Officer and member of the board of directors of Gamida Cell, Ltd. (NASDAQ: GMDA), a pioneer in cell therapies, since September 2022, Ms. Jenkins brings more than 20 years of leadership experience in large and small biotech and pharmaceutical companies, with a focus on commercial launch and corporate strategy roles. Prior to joining Gamida Cell, Ms. Jenkins served as the chief commercial and business officer at Lyndra Therapeutics, Inc., a clinical-stage biopharmaceutical company, where she established and led global commercial, business development, corporate strategy, and portfolio management across multiple therapeutic areas. Prior to Lyndra Therapeutics, Ms. Jenkins served as senior vice president and business unit head of vaccines at Emergent BioSolutions, Inc. (NYSE: EBS) where she oversaw the company's largest therapeutic division from discovery through commercialization. Ms. Jenkins also served as chief commercial officer and U.S. business head at Aquinox Pharmaceuticals, Inc. (NASDAQ: AQXP). Additionally, Ms. Jenkins has held senior commercial and business development positions at Relypsa, Inc. (NASDAQ: RLYP), Actavis (now Teva Pharmaceuticals Ltd.) (NSDAQ: TEVA), Pfizer (NSDAQ: PFE) and Medimmune, LLC (now AstraZeneca) (NASDAQ:AZN). Ms. Jenkins holds a Master of Science in biotechnology and biotech business enterprise from The Johns Hopkins University, a Bachelor of Arts in psychology and biology from Indiana University, and a certificate of achievement in General Management as a Kellogg Executive Scholar. Ms. Jenkins was recognized in 2022 as one of the PharmaVoice 100, one of the industry’s 100 Most Inspiring Leaders, Disrupter Category, for change agents who define excellence in leadership in biopharma. Our Board believes that Ms. Jenkins’ extensive experience in the commercialization of pharmaceutical products, her business development and corporate strategy expertise and her experience in senior leadership roles across several biopharmaceutical companies qualifies her to serve on our Board of Directors.